{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:07:05Z","timestamp":1783645625428,"version":"3.55.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.3816\/cbc.2004.s.008","type":"journal-article","created":{"date-parts":[[2008,9,11]],"date-time":"2008-09-11T21:04:18Z","timestamp":1221167058000},"page":"S6-S12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"S1","title":["The ATAC (Arimidex\u00ae, Tamoxifen, Alone or in Combination) Trial: An Update"],"prefix":"10.3816","volume":"5","author":[{"given":"Aman U.","family":"Buzdar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CBC.2004.s.008_bib1","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","article-title":"Tamoxifen for early breast cancer: an overview of the randomised trials","volume":"351","author":"Early Breast Cancer Trialists' Collaborative Group","year":"1998","journal-title":"Lancet"},{"key":"10.3816\/CBC.2004.s.008_bib2","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/jnci\/88.21.1529","article-title":"Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors","volume":"88","author":"Fisher","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CBC.2004.s.008_bib3","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S0002-9343(99)80251-4","article-title":"The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women","volume":"99","author":"Grey","year":"1995","journal-title":"Am J Med"},{"key":"10.3816\/CBC.2004.s.008_bib4","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1056\/NEJM200206063462319","article-title":"Uterine sarcoma associated with tamoxifen use","volume":"346","author":"Wysowski","year":"2002","journal-title":"N Engl J Med"},{"key":"10.3816\/CBC.2004.s.008_bib5","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/bjc.1996.531","article-title":"Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer","volume":"74","author":"Geisler","year":"1996","journal-title":"Br J Cancer"},{"key":"10.3816\/CBC.2004.s.008_bib6","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1200\/JCO.2000.18.22.3748","article-title":"Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study","volume":"18","author":"Bonneterre","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2004.s.008_bib7","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1002\/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y","article-title":"Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma","volume":"92","author":"Bonneterre","year":"2001","journal-title":"Cancer"},{"key":"10.3816\/CBC.2004.s.008_bib8","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<730::AID-CNCR10>3.0.CO;2-0","article-title":"A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group","volume":"79","author":"Buzdar","year":"1997","journal-title":"Cancer"},{"key":"10.3816\/CBC.2004.s.008_bib9","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/0959-8049(95)00014-3","article-title":"A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer","volume":"32A","author":"Jonat","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.3816\/CBC.2004.s.008_bib10","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2000.18.22.3758","article-title":"Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group","volume":"18","author":"Nabholtz","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2004.s.008_bib11","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/S0140-6736(02)09088-8","article-title":"Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial","volume":"359","author":"The ATAC Trialists' Group","year":"2002","journal-title":"Lancet"},{"key":"10.3816\/CBC.2004.s.008_bib12","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/cncr.11745","volume":"98","author":"The ATAC Trialists' Group","year":"2003","journal-title":"Cancer"},{"issue":"suppl 1","key":"10.3816\/CBC.2004.s.008_bib13","first-page":"S7","article-title":"Analysis of time to recurrence in the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial according to estrogen receptor and progesterone receptor status","volume":"82","author":"Dowsett M on behalf of the ATAC Trialists Group","year":"2003","journal-title":"Breast Cancer Res Treat"},{"issue":"suppl 1","key":"10.3816\/CBC.2004.s.008_bib14","first-page":"S29","article-title":"The endometrial cancer data from the ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial indicates a protective effect of anastrozole (Arimidex) upon the endometrium","volume":"82","author":"Duffy","year":"2003","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2004.s.008_bib15","first-page":"25","article-title":"The time course of bone fractures observed in the ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial","volume":"22","author":"Locker","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2004.s.008_bib16","unstructured":"Eastell R. Effect of anastrozole on bone mineral density: 2 year results of the Arimidex (anastrozole), Tamoxifen, Alone or in Combination (ATAC) trial. Poster presented at: 25th American Society for Bone and Mineral Research Annual Meeting; September 19-23, 2003; Minneapolis, MN."},{"key":"10.3816\/CBC.2004.s.008_bib17","unstructured":"Fallowfield L, Cella D. Assessing the quality of life of postmenopausal women randomized into the ATAC adjuvant breast cancer trial. Presented at: The 8th International Conference: Primary Therapy of Early Breast Cancer; St. Gallen, Switzerland; 2003 (Abstract #97)."},{"key":"10.3816\/CBC.2004.s.008_bib18","first-page":"40a","article-title":"Assessing the quality of life (QOL) of postmenopausal (PM) women randomized into the ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer (BC) trial","volume":"21","author":"Fallowfield","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2004.s.008_bib19","first-page":"40a","article-title":"The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) early breast cancer (EBC) trial in postmenopausal (PM) patients: endometrial sub-protocol results","volume":"21","author":"Duffy","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2004.s.008_bib20","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/978-3-642-55647-0_9","article-title":"Aromatase inhibitors in prevention: data from the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study)","volume":"163","author":"Cuzick","year":"2003","journal-title":"Recent Results Cancer Res"},{"issue":"suppl 1","key":"10.3816\/CBC.2004.s.008_bib21","first-page":"S156","article-title":"Beneficial side-effect profile of anastrozole compared with tamoxifen confirmed by additional 7 months of exposure data: a safety update from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial","volume":"76","author":"Sainsbury","year":"2002","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2004.s.008_bib22","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"issue":"suppl 1","key":"10.3816\/CBC.2004.s.008_bib23","first-page":"S31","article-title":"Changes in bone mineral density caused by anastrozole or tamoxifen in combination with goserelin (\u00b1zoledronate) as adjuvant treatment for hormone receptor-positive premenopausal breast cancer: results of a randomized multicenter trial","volume":"76","author":"Gnant","year":"2002","journal-title":"Breast Cancer Res Treat"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911704049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911704049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:08:16Z","timestamp":1761512896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820911704049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":23,"alternative-id":["S1526820911704049"],"URL":"https:\/\/doi.org\/10.3816\/cbc.2004.s.008","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2004,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The ATAC (Arimidex\u00ae, Tamoxifen, Alone or in Combination) Trial: An Update","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CBC.2004.s.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}